Thermo Fisher Scientific Inc. $TMO Shares Sold by Evercore Wealth Management LLC

Evercore Wealth Management LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 266,753 shares of the medical research company’s stock after selling 8,002 shares during the period. Thermo Fisher Scientific makes up about 2.1% of Evercore Wealth Management LLC’s portfolio, making the stock its 18th biggest holding. Evercore Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $131,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Assetmark Inc. boosted its stake in shares of Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after purchasing an additional 7,023 shares during the period. North Dakota State Investment Board purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $7,505,000. Northstar Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $3,250,000. Boston Trust Walden Corp boosted its position in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after buying an additional 3,873 shares during the period. Finally, Xponance LLC grew its stake in shares of Thermo Fisher Scientific by 8.1% in the fourth quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock worth $34,358,000 after acquiring an additional 4,436 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.7%

Shares of NYSE TMO opened at $558.79 on Tuesday. The business has a 50-day moving average of $496.34 and a two-hundred day moving average of $512.33. The company has a market capitalization of $207.66 billion, a price-to-earnings ratio of 30.06, a price-to-earnings-growth ratio of 2.51 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 25.07 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Piper Sandler lifted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Finally, Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $617.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.